Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

0.4118 -0.0266 (-6.07%)
Streaming Delayed Price Updated: 2:30 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verrica Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Mid-Day Market Update: Gold Drops Over 1%; StoneMor Shares Jump
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 80 points on Wednesday. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 215 companies set new 52-week lows. 
Via Benzinga
Mid-Morning Market Update: Markets Rise; Nasdaq Gains 100 Points
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 100 points on Wednesday. 
Via Benzinga
Why Is Verrica Pharmaceuticals (VRCA) Stock Plunging 55% Today?
VRCA stock is sinking over 50% in morning trading after the FDA declined to approve the company's treatment for "a viral skin disease." 
Via InvestorPlace
Why Verrica Pharma Shares Are Plunging Today
Via Benzinga
Recap: Verrica Pharmaceuticals Q1 Earnings
Verrica Pharmaceuticals (NASDAQ:VRCA) reported its Q1 earnings results on Monday, May 9, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) gained 178.3% to $0.3762 as the company announced it increased retail distribution across Canada with Loblaw Companies. 
Via Benzinga
Express (EXPR) Stock Pops 9% After Better-Than-Expected Q1 Earnings
Express (EXPR) stock is rising higher on Wednesday after the fashion retailer reported results for the first quarter of 2022. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2022
Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of... 
Via Benzinga
Why Is Dick’s Sporting Goods (DKS) Stock Down 6% Today?
Dick's Sporting Goods (DKS) stock is taking a beating on Wednesday after the retailer released its earnings report for Q1 2022. 
Via InvestorPlace
The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Telsey Advisory Group cut Ralph Lauren Corporation (NYSE: RL) price target from $160 to $140. Ralph Lauren shares fell 3% to $88.40 in pre-market trading. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Rise and shine, traders! We're starting off the day with a breakdown of the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
21 Stocks Moving in Wednesday's Pre-Market Session
Gainers The Singing Machine Company, Inc. (NASDAQ: MICS) shares rose 47.3% to $4.05 in pre-market trading. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
'Pharma Bro' Martin Shkreli Says He Toyed With Crypto On Uniswap — Vitalik Buterin Reacts
Martin Shkreli, who infamously raised the price of an antiparasitic drug by 5,455% in 2017, sang praises of Ethereum (CRYPTO: ETH)-based decentralized cryptocurrency exchange Uniswap (UNI) after... 
Via Benzinga
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
Via Benzinga
7 Biotech Stocks With Key Catalysts for May
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 435 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 211 companies set new 52-week lows. 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2022
Upgrades For Alpha Metallurgical Resources Inc (NYSE:AMR), B. Riley Securities upgraded the previous rating of Neutral to Buy. For the fourth quarter, Alpha Metallurgical... 
Via Benzinga
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug... 
Via Benzinga
FDA Accepts Verrica's Resubmission For VP-102 For Contagious Skin Disease
The FDA has accepted Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) resubmitted marketing application seeking approval for VP-102 to treat molluscum contagiosum (... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Calliditas Therapeutics (NASDAQ: 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.